8-K: Envista Posts Strong Q4, Full-Year 2025 Results; Issues 2026 Outlook

Envista Holdings Corporation announced robust fourth quarter and full-year 2025 financial results, driven by significant core revenue and adjusted EBITDA growth, alongside positive 2026 guidance.

Summary

• Q4 2025 sales reached $751 million, with core sales growth of 10.8% over the fourth quarter of 2024.
• Full-year 2025 sales were $2,719 million, achieving 6.5% core sales growth over fiscal year 2024.
• Adjusted EBITDA for Q4 2025 was $111 million, a 22% year-on-year increase, with an adjusted EBITDA margin of 14.8% (+90 bps year-on-year).
• Full-year 2025 adjusted EBITDA was $372 million, a 26% year-on-year increase, with an adjusted EBITDA margin of 13.7% (+190 bps year-on-year).
• Adjusted diluted EPS for Q4 2025 was $0.38, up 58% year-on-year, and for full-year 2025 was $1.19, up 63% year-on-year.
• The company returned $166 million to shareholders through share repurchases during the full-year 2025.
• All major businesses and geographies delivered positive growth in 2025, supported by a 30% increase in customer training.
• Spark achieved a positive operating margin in the second half of 2025, and company-wide G&A expense was reduced by 10% compared to 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, driven by strong core revenue and adjusted EBITDA growth, significant EPS improvement, and a confident outlook for 2026, despite a slight dip in cash flow compared to the prior year.

Positives

• Strong core revenue growth of 10.8% in Q4 2025 and 6.5% for the full-year 2025.
• Significant adjusted EBITDA growth of 22% in Q4 2025 and 26% for the full-year 2025.
• Improved adjusted EBITDA margins: 14.8% in Q4 2025 (+90 bps) and 13.7% for the full-year 2025 (+190 bps).
• Substantial increase in adjusted diluted EPS: 58% in Q4 2025 and 63% for the full-year 2025.
• Positive growth across all major businesses and geographies in 2025.
• Spark achieved a positive operating margin in the second half of 2025.
• Company-wide G&A expense reduced by 10% compared to 2024.
• Double-digit increase in R&D investment to support continued innovation-led growth.
• Improved employee engagement scores with record participation in the annual employee survey.
• Donated over $2 million in cash and products in 2025 to communities in need through the Envista Smile Project.
• Repurchased 9.2 million shares for approximately $166 million during the twelve months ended December 31, 2025.
• Robust free cash conversion of 114% for the full-year 2025.

Negatives

• Operating cash flow for Q4 2025 was $108 million, a decrease from $132 million in Q4 2024.
• Free cash flow for Q4 2025 was $92 million, a decrease from $124 million in Q4 2024.
• Operating cash flow for the full-year 2025 was $276 million, a decrease from $337 million in the full-year 2024.
• Free cash flow for the full-year 2025 was $231 million, a decrease from $303 million in the full-year 2024.

Risks

• Conditions in the U.S. and global economy, including the impact of inflation and increasing interest rates, slower economic growth, or recession.
• International economic, political, legal, compliance, and business factors.
• The impact of debt obligations on operations and liquidity.
• Developments and uncertainties in trade policies and regulations, including tariffs or other impositions on imported goods.
• Contractions or growth rates and cyclicality of markets served.
• Risks relating to product manufacturing, commodity costs, and surcharges.
• Ability to adjust purchases and manufacturing capacity to reflect market conditions.
• Reliance on sole or limited sources of supply.
• Disruptions relating to war, terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues, and other events.
• Security breaches or other disruptions of information technology systems or violations of data privacy laws.
• Security breaches or other disruptions affecting external information technology contractors, vendors, or other service providers.
• Fluctuations in inventory of distributors and customers.
• Loss of a key distributor.
• Relationships with and the performance of channel partners.
• Competition.
• Ability to develop and successfully market new products and services.
• Ability to attract, develop, and retain key personnel.
• The potential for improper conduct by employees, agents, or business partners.
• Compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry).
• The results of clinical trials and perceptions thereof.
• Penalties associated with any off-label marketing of products.
• Modifications to products that require new marketing clearances or authorizations.
• Ability to effectively address cost reductions and other changes in the health care industry.
• Ability to successfully identify and consummate appropriate acquisitions and strategic investments.
• Ability to integrate acquired businesses and achieve the anticipated benefits of such acquisitions.
• Contingent liabilities relating to acquisitions, investments, and divestitures.
• Ability to adequately protect intellectual property.
• The impact of restructuring activities on the ability to grow.
• Risks relating to impairment charges for goodwill and intangible assets.
• Changes in accounting standards and subjective assumptions, estimates, and judgment by management.
• Currency exchange rates.
• Changes in tax laws applicable to multinational companies.
• Litigation and other contingent liabilities including intellectual property and environmental, health, and safety matters.
• Risks relating to product, service, or software defects.
• The impact of regulation on demand for products and services.
• Labor matters.

Future Outlook

For the full year 2026, Envista projects core sales growth of 2% to 4%, adjusted EBITDA growth of 7% to 13%, adjusted diluted earnings per share between $1.35 and $1.45, and free cash conversion of approximately 100%.

Management Comments

• "With our disciplined focus on Growth, Operations, and People, Q4 2025 marked another quarter of continued progress for Envista."
• "We delivered 10.8% core revenue growth and 22% adjusted EBITDA growth in Q425, and 6.5% core revenue growth and 26% EBITDA growth for the full-year 2025."
• "In the process, we posted positive growth in all major businesses and geographies, made broad-based improvements in employee development and engagement, and returned $166 million to shareholders through share repurchases."
• "Congratulations to our teams around the world for making all this progress possible."

Industry Context

StockSavvy.ai notes that Envista's strong performance in core revenue and adjusted EBITDA growth, coupled with strategic investments in R&D and customer training, positions it favorably within the competitive dental industry. The focus on the Envista Business System (EBS) and operational efficiencies, such as Spark achieving positive operating margin, suggests a robust internal strategy to navigate market dynamics and maintain profitability amidst broader economic uncertainties.

Comparison to Industry Standards

• Envista's 10.8% Q4 2025 core sales growth and 6.5% full-year 2025 core sales growth are strong indicators, potentially outperforming some peers in the dental equipment and consumables sector, which often sees mid-single-digit growth. For example, Dentsply Sirona typically reports mid-single-digit organic growth, making Envista's Q4 core sales growth notably strong.
• The 22% Q4 2025 and 26% full-year 2025 adjusted EBITDA growth, along with margin expansion, suggests effective cost management and operational leverage, which could be above the industry average for mature dental companies.
• The 114% free cash conversion for FY 2025 is a robust figure, indicating strong cash generation efficiency, potentially exceeding benchmarks set by companies like Henry Schein, which also focuses on distribution and services.
• The double-digit increase in R&D investment aligns with industry leaders who continuously innovate in areas like digital dentistry, implants, and orthodontics to maintain competitive advantage.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, share repurchases, and positive 2026 guidance.
• Employees: Improved employee engagement scores and record participation in the annual survey indicate a positive internal environment.
• Customers: Increased customer training (30% increase vs 2024) and double-digit R&D investment suggest continued focus on product innovation and support.
• Communities: Over $2 million donated in cash and products through the Envista Smile Project.

Next Steps

• Investor conference call on February 5, 2026, at 2:00 P.M. PT to discuss quarterly results and 2026 outlook.
• Webcast and slide presentation available on the "Investors" section of the company's website, www.envistaco.com, under the subheading "Events & Presentations."
• A replay of the webcast will be available in the same section of the website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

Key Dates

Recommendation

The company delivered exceptional Q4 and full-year 2025 results, significantly outperforming prior periods in core sales growth, adjusted EBITDA, and adjusted EPS. The positive 2026 guidance, coupled with strategic initiatives like increased R&D investment, operational efficiencies (EBS, Spark profitability), and substantial share repurchases, demonstrates strong management execution and a clear path for continued value creation. Despite a slight decrease in cash flow, the overall financial health and future prospects presented in the filing warrant a strong buy recommendation for long-term investors.

Keywords

Envista Holdings, NVST, Dental Industry, Financial Results, Earnings Report, Q4 2025, Full Year 2025, 2026 Guidance, Core Sales Growth, Adjusted EBITDA, EPS, Share Repurchases, Dental Implants, Orthodontics, Dental Imaging, Dental Consumables